502/145 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 31 July 2003 (31.07.2003)

English

(10) International Publication Number WO 03/062278 A1

C07K 16/28, (51) International Patent Classification7: C12N 5/20, A61K 39/395, A61P 37/02

(21) International Application Number: PCT/AU03/00084

(22) International Filing Date: 24 January 2003 (24.01.2003)

(25) Filing Language:

English (26) Publication Language:

(30) Priority Data: 25 January 2002 (25.01.2002) 60/350,961

(71) Applicant (for all designated States except US): G2 THERAPIES LTD [AU/AU]; 384 Victoria Street, Darlinghurst, NSW 2010 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MACKAY, Charles, Reay [AU/AU]; 1 Belah Gardens, Vaucluse, NSW 2030

(74) Agent: F B RICE & CO; 139-141 Rathdowne Street, Carlton, VIC 3053 (AU).

Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR

(57) Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.